At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
XRES4 Neuro Claim Study
In Brief
A clinical study evaluating Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology. and Normal dose DSA with conventional X-ray technology for Arteriovenous Malformations and 3 related conditions. Completed, enrolled 20 participants across 1 site.
Detailed Summary
ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. This is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. Furthermore, smaller focal spot sizes and shorter pulses are used, which are known to positively influence image quality . The final effect on the clinical image quality is investigated in this study.
Study Details
Timeline
Interventions
Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.